Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma-Reference-Cited by-同舟云学术

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

Published:2015-01-15 Issue:3 Volume:125 Page:443-448
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kumar Shaji K.¹^ORCID,LaPlant Betsy²,Chng Wee Joo³,Zonder Jeffrey⁴,Callander Natalie⁵,Fonseca Rafael⁶,Fruth Briant²,Roy Vivek⁷,Erlichman Charles⁸,Stewart A. Keith⁶

Affiliation:

1. Division of Hematology and

2. Department of Biostatistics, Mayo Clinic, Rochester, MN;

3. Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore;

4. Karmanos Cancer Center, Detroit, MI;

5. Section of Hematology and Bone Marrow Transplant, University of Wisconsin, Madison, WI;

6. Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ;

7. Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL; and

8. Division of Medical Oncology, Mayo Clinic, Rochester, MN

Abstract

Key Points Dinaciclib is a novel cdk inhibitor that demonstrates single agent activity in myeloma. Dinaciclib has a safety profile that is easily manageable.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/3/443/1344421/443.pdf

Reference26 articles.

1. Treatment of newly diagnosed multiple myeloma: advances in current therapy.;Kumar;Med Oncol,2010

2. Clinical course of patients with relapsed multiple myeloma.;Kumar;Mayo Clin Proc,2004

3. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia.;Kumar,2012

4. Clonal competition with alternating dominance in multiple myeloma.;Keats;Blood,2012

5. Targeting the cell cycle: a new approach to cancer therapy.;Schwartz;J Clin Oncol,2005

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dinaciclib inhibits the growth of acute myeloid leukemia cells through either cell cycle-related or ERK1/STAT3/MYC pathways;Toxicology in Vitro;2024-04

2. Design, synthesis, and biological evaluation of N-(pyridin-3-yl)pyrimidin-4-amine analogues as novel cyclin-dependent kinase 2 inhibitors for cancer therapy;Bioorganic Chemistry;2024-02

3. Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma;Archiv der Pharmazie;2024-01-31

4. Targeting the DNA damage response in hematological malignancies;Frontiers in Oncology;2024-01-29

5. Synthesis of 4-(pyrazol-1-yl)pyrimidines from 4-hydrazinopyrimidines and investigation of their structure and some chemical properties;Journal of Molecular Structure;2024-01